Session 10 –New Frontiers in Therapeutics
Date: 24 July (Friday) 09:00 – 10:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Dr. Wu is an entrepreneur and an expert in biologics, including recombinant proteins, vaccines, and therapeutic antibodies. He is the key member to develop anti-PSGL-1 monoclonal antibody for the treatment of many different autoimmune diseases. He is also the project leader to develop anti-H7N9 mAb for pandemic influenza virus, anti-ENO1 mAb for multiple sclerosis and cancers, and anti-Kp mAb for multiple-drug-resistant bacteria. He and his team used anti-GloboH mAb to build an antibody platform, including native antibody, asymmetric bi-specific antibody and tri-mannose-linked antibody-drug-conjugate (ADC), to treat different cancers.
He was an Associate Professor of the Institute of Molecular Medicine, National Taiwan University during 1995~2000 before he helped to found AbGenomics Corp., a biotech company specialized in developing therapeutic antibodies in 2000. Over the past 20+ years, he has produced over 30 publications in peer-reviewed scientific journals and 8 international patents, all of which were licensed-out for commercial applications.
During his tenure in AbGenomics Corp. as Chief Technology Officer, he led the R&D team to build a product pipeline containing several therapeutic antibodies for the treatment of autoimmune diseases and different cancers. Two of products advanced to clinical development. One of the products was licensed to Boehringer Ingelheim in 2005.
Dr. Wu joined DCB first as the Executive Director of the Institute of Biologics and was later promoted to Vice President and subsequently to the current position as the President in 2018 because of his brilliant achievement in building product pipelines and subsequent licensing out of several of those products. In addition to continuing to build a strong product pipeline and expand/diversify the research directions, Dr. Wu created Innovation & Entrepreneurship Core (IEC) in DCB to encourage entrepreneurship in the institute. IEC will fully utilize the strength of DCB’s internal RD and BD capabilities flexibly to leverage any external resources, including but not limited to academia and financial, to found biotech startups with great potential. Proposals for collaboration are welcomed.
Dr. Wu was a Jane Coffin Childs Fellow, and receives his Ph.D. degree in the Department of Biological Chemistry, University of Maryland at Baltimore, U.S.A. and a bachelor degree in the Department of Botany, National Taiwan University, Taiwan.